Codeine Sulfate

Selected form

Codeine Sulfate

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codeine Sulfate

Property	Description
Active ingredient	Codeine
Form	Sulfate salt (Tablet, Oral solution)
Pharmacological class	Opioid analgesic, Antitussive
Common use	Pain relief, Cough suppression
Origin	Semisynthetic

What Type of Medicine is Codeine Sulfate? (Identity and Classification)

Codeine Sulfate is a semisynthetic opioid medication classified primarily as a narcotic analgesic and a central antitussive (cough suppressant). The substance itself is the stable sulfate salt form of the active drug codeine, a compound derived from the natural opium alkaloid, morphine. This classification confirms its placement among medicines that act centrally on the nervous system. Codeine is utilized as a medicine for managing mild to moderate pain, backed by clinical use confirming its therapeutic efficacy.

Codeine Sulfate Composition and General Purpose (Form and Use)

The composition features codeine as the active ingredient, formulated as a sulfate salt to ensure consistent stability for preparation as an oral tablet or oral solution. The drug's general therapeutic purpose is its dual capacity for providing relief from discomfort, specifically for mild to moderate pain, and for suppressing persistent, non-productive coughing. It is often prepared as a single-ingredient product but is widely integrated into popular combination formulations containing non-opioids like acetaminophen. Its most typical use scenario involves managing short-term pain or controlling a chronic, dry cough.

High-Level Action Principle

The medication functions as a prodrug, meaning the administered codeine molecule must be metabolized in the liver to become fully effective. This process converts a fraction of the codeine into active morphine, which then binds to mu-opioid receptors in the central nervous system, an action that fundamentally alters the body's perception of pain. This central mechanism provides the general benefit of suppressing persistent coughing by acting directly on the brain's cough center, distinguishing its effect from local, topical treatments.

Regulatory References

What side effects are possible with Codeine Sulfate?

Possible Side Effects and Safety Information

The safety profile of Codeine Sulfate is derived from official government regulatory documents, detailing both common reactions and serious risks. The most critical safety information is framed around its opioid classification.

Common and Expected Adverse Reactions

Adverse effects listed as common in official labeling primarily affect the nervous system and the digestive tract. These effects are often most noticeable during the initial period of use.

System-Organ Class	Common Adverse Reaction
Nervous System	Drowsiness, Sedation, Dizziness, Lightheadedness
Gastrointestinal	Nausea, Vomiting, Constipation
Other	Sweating, Shortness of breath

Serious Adverse Reactions and Key Warnings

Regulatory authorities highlight severe risks, often in a Boxed Warning, emphasizing potentially fatal outcomes and risks associated with chronic use:

Life-Threatening Respiratory Depression: The most serious documented risk, with increased potential during therapy initiation or dose increases.
Addiction, Abuse, and Misuse: Risk of developing dependence and substance use disorder.
Other Serious Risks: Severe Hypotension (low blood pressure), Serotonin Syndrome (with certain co-medications), Adrenal Insufficiency, and Paralytic Ileus (intestinal obstruction).

Population-Specific Safety Restrictions

Use of Codeine Sulfate is strictly contraindicated (forbidden) for specific, vulnerable patient groups, regardless of the therapeutic need:

Children under 12 years of age.
Ultra-Rapid Metabolizers (individuals with certain genetic polymorphisms, due to rapid conversion to excessive morphine).
Post-operative management in children and adolescents (under 18) following tonsillectomy and/or adenoidectomy.
The medication is not recommended for breastfeeding mothers due to the risk of serious adverse reactions in the infant. Use is also restricted in patients with significant respiratory depression or concurrent use of Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

The official regulatory documentation identifies overdose of Codeine Sulfate as a serious acute opioid toxicity event, primarily characterized by severe central nervous system (CNS) and respiratory depression.

Documented Overdose Presentations and Severity

Overdose manifestations documented in official sources include unresponsiveness, profound sedation, stupor, and potentially coma. The primary life-threatening outcome is fatal respiratory depression, which is characterized by slow or shallow breathing and may result in cyanosis (bluish skin or lips). Other physical signs listed in regulatory information include pinpoint pupils (miosis), cold and clammy skin, and severe hypotension.

When to Seek Immediate Help

Regulatory guidance strictly mandates that immediate medical attention must be sought for any suspected overdose. This includes calling emergency services right away if severe symptoms of toxicity are observed, or following the accidental ingestion of the medicine, particularly by a child, which is officially documented as potentially fatal even at low doses. Emergency management involves administering the specific opioid antagonist, Naloxone, and providing symptomatic and supportive measures, such as breathing support.

Population-Specific Risk

Official labeling emphasizes that children under 12 years of age and individuals identified as ultra-rapid metabolizers face a heightened, documented risk of life-threatening respiratory depression and death. This risk is also officially noted as being elevated in elderly or debilitated patients.

Therapeutic Uses of Codeine Sulfate

The therapeutic application of Codeine Sulfate focuses on managing pain and suppressing cough, providing supportive relief for symptoms that create noticeable functional strain. The medication is relevant across therapeutic domains where short-term symptomatic assistance is needed.

Codeine is commonly used to help with pain and cough symptoms, relevant for mild to moderate pain when supportive symptomatic assistance is needed, and for persistent, non-productive cough. The primary indications include relief from pain and management of cough.

Symptomatic Relief for Mild to Moderate Pain

Codeine Sulfate is commonly used across conditions presenting with systemic or localized discomfort, such as after dental procedures or minor injuries. This analgesic support helps address symptom clusters that may become intense or disruptive by easing the symptom intensity. It contributes to improved comfort during periods of heightened symptoms, which assists with maintaining functional stability.

Management of Persistent, Non-Productive Cough

The medication is applied in addressing symptoms related to heightened physiological activity, specifically a persistent cough. It is generally relevant in conditions characterized by periods of heightened symptoms, such as those associated with common colds, where a dry cough interferes with daily functioning. By addressing the cough pattern, it offers symptomatic relief that helps patients cope more steadily with difficult episodes, especially when symptoms disrupt rest.

Quick Facts: Therapeutic Use

Codeine Sulfate is applied in settings where symptoms become more noticeable, offering supportive relief when acute manifestations interfere with function. It assists with managing symptoms that interfere with daily functioning across acute and chronic contexts.

Regulatory References

National Institutes of Health (NIH) MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Codeine Sulfate use is strictly defined by regulatory authorities based on age, genetic factors, and pre-existing medical conditions, primarily due to the risk of respiratory depression.

Contraindicated Populations (Must Not Use)

Pediatric Age: All children younger than 12 years of age are prohibited from using the medicine.
Pediatric Post-Surgical: Children younger than 18 years of age following tonsillectomy and/or adenoidectomy must not use Codeine Sulfate.
Metabolic Risk: Individuals who are known ultra-rapid metabolizers of codeine (due to CYP2D6 activity) are strictly contraindicated.
Respiratory Status: Patients with significant respiratory depression or acute/severe bronchial asthma in an unmonitored setting are prohibited from use.
Gastrointestinal: Patients with known or suspected gastrointestinal obstruction, including paralytic ileus, must not use the medicine.

Restricted and Conditional Use

Breastfeeding: Use is not recommended in breastfeeding mothers due to the risk of serious adverse reactions in the infant.
Organ Function: Use requires caution in geriatric patients and those with hepatic impairment or renal impairment.
Comorbidities: Caution is required in patients with Chronic Pulmonary Disease or conditions resulting in Increased Intracranial Pressure.

What should I know about interactions with other medicines?

Codeine Sulfate has significant documented interactions with certain medicinal product categories that may impact its metabolism, efficacy, and safety profile.

Interacting Agents and Constraints

Category	Official Restriction or Constraint	Mechanistic Basis (Regulatory Statement)
MAO Inhibitors (e.g., Isocarboxazid, Phenelzine)	Contraindicated for concurrent use or use within 14 days of stopping MAOIs.	Potentiation of morphine's effects, including respiratory depression and coma.
CNS Depressants (e.g., Benzodiazepines, Alcohol, General Anesthetics)	Concomitant use must be reserved for when alternatives are inadequate. Limit dosages and duration to the minimum required.	Additive CNS depressive effects, resulting in profound sedation, respiratory depression, coma, and death.
CYP2D6 Inhibitors (e.g., Quinidine, Amiodarone)	Requires close patient monitoring for reduced efficacy or opioid withdrawal. Dosage adjustments may be needed upon initiation or discontinuation.	Inhibition of the enzyme that converts codeine to its active metabolite, morphine, leading to decreased morphine concentrations.
CYP3A4 Inhibitors/Inducers (e.g., Macrolides, Azole-antifungals, Rifampin)	Requires close patient monitoring for signs of opioid toxicity or reduced efficacy.	Alteration of codeine plasma concentrations, affecting the risk of adverse reactions or reduced efficacy.
Opioid Agonists/Antagonists (e.g., Pentazocine, Buprenorphine)	Avoid concomitant use.	May reduce the analgesic effect of codeine or precipitate withdrawal symptoms.

The regulatory labeling dictates these precautions due to the risks associated with altered codeine metabolism and synergistic depressant effects on the central nervous system. Use is also contraindicated in any patient known to be a CYP2D6 ultra-rapid metabolizer due to the risk of life-threatening respiratory depression from rapid morphine conversion.

Mechanism of Action

Codeine primarily functions as a prodrug, requiring metabolic conversion by the Cytochrome P450 2D6 ( CYP2D6) enzyme into its active O-demethylated metabolite, morphine. Morphine, along with the active metabolite codeine-6-glucuronide, then acts as an agonist on the mu-Opioid Receptors ( MOR) found throughout the central nervous system ( CNS) and spinal cord.

This vital enzymatic step determines the ultimate receptor activation level, as insufficient conversion due to genetic variability leads to a failure in MOR agonism.

Activation of MOR initiates an inhibitory cascade involving Gi/o proteins, which decreases neuronal excitability and hyperpolarizes the nerve cell. This molecular action directly suppresses the release of excitatory neurotransmitters (like Substance P), effectively blocking the ascent and transmission of nociceptive signals up the spinal cord. This mechanism modulates the transmission of nociceptive signals by acting on the CNS's core pathway for signal processing.

Codeine's metabolites also directly engage mu-opioid receptors located in the brainstem, specifically within the medulla oblongata that governs the involuntary cough reflex. This action selectively dampens the neuronal excitability of the cough center. The result is a dampening of the efferent cough command signal, modulating this involuntary physiological response.

Dosage and Administration Information

How Codeine Sulfate is Used: General Administration Overview

Codeine Sulfate is prescribed for oral administration only. It is supplied as immediate-release tablets (15 mg, 30 mg, 60 mg) and as an oral solution (30 mg/5 mL), ensuring a consistent route of delivery. The administration protocol emphasizes using the lowest effective dosage for the shortest duration necessary to manage symptoms.

Standard Dosage and Frequency Patterns

For adult analgesia, the usual single dose ranges from 15 mg to 60 mg. This medication is typically taken up to every 4 to 6 hours as needed, provided the total amount administered does not exceed the maximum daily dose of 360 mg. General clinical practice involves limiting the use of codeine for acute moderate pain relief to a maximum duration of three days.

Preparation and Population Adjustments

Specific administration requirements exist to ensure accuracy. When using the oral solution, a calibrated measuring device must be utilized, as household measuring tools can lead to inaccurate dosing. For older adults and patients with hepatic or renal impairment, caution is necessary, and treatment is typically initiated at the low end of the dosage range. If the medication has been used for an extended period, physical dependence may occur, and cessation involves a safe, gradual tapering schedule rather than abrupt discontinuation to manage withdrawal.

Recent Clinical Evidence

Codeine Sulfate: Recent Clinical Evidence

Codeine Sulfate is an opioid analgesic indicated for the management of mild to moderately severe pain where the use of an opioid is considered appropriate. Current clinical literature and regulatory guidance focus heavily on clarifying its role, particularly given the variability in individual patient response due to genetic factors and the potential for harm.

Efficacy in Pain Management

Meta-analyses of randomized controlled trials (RCTs) have consistently evaluated the effectiveness of codeine, often in combination with non-opioid analgesics like acetaminophen or ibuprofen, for acute pain relief.

Studies involving single doses of codeine (60 mg), typically for acute postoperative pain, showed a statistically significant difference in pain relief when compared to a placebo over a four- to six-hour period. The Number Needed to Treat (NNT) to achieve at least 50% pain relief over this time frame has been established in the range of 8 to 12 in broad acute pain settings.
Research suggests that combination products containing low-dose codeine (e.g., leq 30 mg) may provide greater pain relief for some patients experiencing high levels of pain when compared to placebo or the non-opioid analgesic alone.
Evidence generally does not support the long-term use of codeine for chronic non-cancer pain, with many guidelines recommending maximized non-pharmacological and non-opioid treatments first.

Safety and Genetic Variability

Recent regulatory updates have emphasized the importance of patient safety, focusing on the drug's metabolism. Codeine is a prodrug, and its analgesic effect largely depends on its conversion to morphine by the CYP2D6 enzyme in the liver.

CYP2D6 Status	Potential Clinical Outcome (Observed in Studies)
Ultra-Rapid Metabolizers (UM)	Increased conversion to morphine, leading to higher risk of adverse effects like respiratory depression.
Poor Metabolizers (PM)	Reduced conversion to morphine, leading to potentially insufficient pain relief.

This genetic variability means the analgesic effect can be unpredictable between individuals. Due to the risk of life-threatening respiratory depression, particularly in ultra-rapid metabolizers, the use of codeine has been restricted in certain populations, including children and those who are breastfeeding.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Codeine Sulfate (FAQ)

Q: Does it make you sleepy?

Official product information states that this medicine may cause central nervous system (CNS) effects, which can include drowsiness or sleepiness (somnolence). This is noted as a potential effect in the Warnings and Precautions section of the drug label. Official product information cautions that because of these potential effects, care should be taken when performing tasks requiring mental alertness, such as driving or operating machinery.

Q: Is it safe long-term?

The official regulatory documents contain information on the drug's safety profile based on clinical studies and ongoing surveillance. This includes details on any potential risks or monitoring that may be required for extended or long-term use of the medication. This data is typically found in the sections covering clinical trial results and side effects in the official product information.

Q: Can children 2 years old use it?

Official regulatory labeling specifies the approved age groups for which Codeine Sulfate is indicated. If the label does not specifically include children 2 years old, the official document indicates that the safety and effectiveness of the medication have not been established in that specific age group. The drug is intended for use only according to the stated pediatric indications found in the official product information.

How should Codeine Sulfate be stored and disposed of?

Official Storage Requirements

Codeine Sulfate must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat, moisture, and freezing and should be kept away from direct light. Maintain stability by keeping the medication in its original, tightly closed container.

As a controlled substance, Codeine Sulfate must be stored in a secure location out of the reach and sight of children to prevent accidental ingestion, which carries a high risk of fatal overdose.

Official Disposal Instructions

The primary disposal method is through an authorized drug take-back program or mail-back service. If a take-back option is unavailable and the specific product is not on the FDA's flush list, dispose of the medicine in the household trash. This requires mixing the drug with an undesirable substance (e.g., dirt or cat litter) and sealing the mixture in a container before discarding it. Disposal in the sink or toilet is generally prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

USA

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z